Brief: Cyclerion Therapeutics Announces Cy6463 Data Demonstrating Improved Cellular Energetics In Preclinical Models Of Mitochondrial Disease
17/06/2022 13:10
June 17 (Reuters) - Cyclerion Therapeutics Inc CYCN.O :
* CYCLERION THERAPEUTICS ANNOUNCES CY6463 DATA DEMONSTRATING
IMPROVED CELLULAR ENERGETICS IN PRECLINICAL MODELS OF
MITOCHONDRIAL DISEASE
* CYCLERION THERAPEUTICS -CY6463 ALLEVIATED MITOCHONDRIAL
DYSFUNCTION, REDUCED INFLAMMATION IN PRECLINICAL MODELS OF
MITOCHONDRIAL COMPLEX 1 DEFICIENCY
* CYCLERION THERAPEUTICS - DATA PROVIDE SUPPORT FOR ONGOING
CY6463
CLINICAL STUDIES IN CNS DISEASES ASSOCIATED WITH MITOCHONDRIAL
DYSFUNCTION
Source text for Eikon: ID:nGNX10nsbX
Further company coverage: CYCN.O
((Reuters.Briefs@thomsonreuters.com;))